Promoter hypermethylation rates found in our study fit on intervals reported in the HNSCC literature for DAPK (12 – 71.69%) (Li et al., 2013; Noorlag et al., 2014) and MGMT (18.1 – 58.67%) (Zuo et al., 2004; Strzelczyk et al., 2018), but not for RUNX3 (15 – 70%) (Gao et al., 2009; Zhang et al., 2013). The gene discussed is DAPK1; the disease is head and neck squamous cell carcinoma.